| Non-V600BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer JC Jones, LA Renfro, HO Al-Shamsi, AB Schrock, A Rankin, BY Zhang, ... Journal of Clinical Oncology 35 (23), 2624, 2017 | 346 | 2017 |
| NCCTG N08CA (Alliance): The use of glutathione for prevention of paclitaxel/carboplatin induced peripheral neuropathy: A phase III randomized, double-blind placebo-controlled study AD Leal, R Qin, PJ Atherton, P Haluska Jr, RJ Behrens, C Tiber, ... Cancer 120 (12), 1890, 2014 | 84 | 2014 |
| Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy AD Leal, KC Kadakia, S Looker, C Hilger, K Sorgatz, K Anderson, ... Supportive Care in Cancer 22, 1313-1317, 2014 | 56 | 2014 |
| North Central Cancer Treatment Group/Alliance trial N08CA—the use of glutathione for prevention of paclitaxel/carboplatin‐induced peripheral neuropathy: A phase 3 randomized … AD Leal, R Qin, PJ Atherton, P Haluska, RJ Behrens, CH Tiber, ... Cancer 120 (12), 1890-1897, 2014 | 49 | 2014 |
| Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort AD Leal, CA Thompson, AH Wang, RA Vierkant, TM Habermann, JA Ross, ... International journal of cancer 134 (7), 1741-1750, 2014 | 47 | 2014 |
| Clinical development of immunotherapy for deficient mismatch repair colorectal cancer J Thomas, A Leal, MJ Overman Clinical colorectal cancer 19 (2), 73-81, 2020 | 46 | 2020 |
| An analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy LT Hegerova, AD Leal, DC Grendahl, DK Seisler, KM Sorgatz, ... Supportive Care in Cancer 23, 55-59, 2015 | 34 | 2015 |
| BCR-JAK2 fusion as a result of a translocation (9; 22)(p24; q11. 2) in a patient with CML-like myeloproliferative disease MM Elnaggar, S Agersborg, T Sahoo, A Girgin, W Ma, R Rakkhit, I Zorrilla, ... Molecular cytogenetics 5, 1-6, 2012 | 26 | 2012 |
| Widespread use of complementary and alternative medicine among non-Hodgkin lymphoma survivors S Rausch Osian, AD Leal, C Allmer, MJ Maurer, G Nowakowski, ... Leukemia & lymphoma 56 (2), 434-439, 2015 | 19 | 2015 |
| Variability of performance status assessment between patients with hematologic malignancies and their physicians AD Leal, C Allmer, MJ Maurer, TD Shanafelt, JR Cerhan, BK Link, ... Leukemia & lymphoma 59 (3), 695-701, 2018 | 17 | 2018 |
| Ten-year trends in antiemetic prescribing in patients receiving highly emetogenic chemotherapy CC O'Sullivan, HK Van Houten, LR Sangaralingham, AD Leal, S Shinde, ... Journal of the National Comprehensive Cancer Network 16 (3), 294-299, 2018 | 17 | 2018 |
| Antiemetic prescribing practices using a computerized physician order entry system KC Kadakia, AD Leal, DK Seisler, R Qin, KC Fee-Schroeder, ... Supportive Care in Cancer 22, 217-223, 2014 | 17 | 2014 |
| WEE1 inhibition in combination with targeted agents and standard chemotherapy in preclinical models of pancreatic ductal adenocarcinoma SJ Hartman, SM Bagby, BW Yacob, DM Simmons, M MacBeth, CH Lieu, ... Frontiers in Oncology 11, 642328, 2021 | 16 | 2021 |
| First-in-human phase 1 trial of ELI-002 immunotherapy as treatment for subjects with Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma and other solid tumors. S Pant, M Furqan, RM Abdul-Karim, V Chung, CE Devoe, ML Johnson, ... Journal of Clinical Oncology 40 (16_suppl), TPS2701-TPS2701, 2022 | 12 | 2022 |
| Results from the safety lead-in for a phase II study of pembrolizumab in combination with binimetinib and bevacizumab in patients with refractory metastatic colorectal cancer … CH Lieu, SL Davis, S Leong, AD Leal, PJ Blatchford, GS Sandhu, ... Journal of Clinical Oncology 38 (15_suppl), 4031-4031, 2020 | 11 | 2020 |
| Response to pembrolizumab in patients with mismatch repair deficient (dMMR) colorectal cancer (CRC). AD Leal, J Paludo, HD Finnes, A Grothey Journal of Clinical Oncology 35 (15_suppl), 3558-3558, 2017 | 11 | 2017 |
| AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk with KRAS G12D-or G12R-mutated pancreatic and … EM O'Reilly, ZA Wainberg, CD Weekes, M Furqan, PM Kasi, CE Devoe, ... Journal of clinical oncology 41 (16_suppl), 2528-2528, 2023 | 10 | 2023 |
| Outcome of neoadjuvant treatment for pancreatic cancer in elderly patients: comparative, observational cohort study A Oba, YHA Wu, CH Lieu, C Meguid, KL Colborn, L Beaty, MH Al-Musawi, ... British Journal of Surgery 108 (8), 976-982, 2021 | 10 | 2021 |
| Antibody drug conjugates under investigation in phase I and phase II clinical trials for gastrointestinal cancer AD Leal, A Krishnamurthy, L Head, WA Messersmith Expert opinion on investigational drugs 27 (11), 901-916, 2018 | 9 | 2018 |
| Commonality and clinical, pathological, and prognostic characteristics of non-V600E BRAF mutations (BRAF Mut) in metastatic colorectal cancers (mCRC) compared to V600 BRAF Mut … JC Jones, B Kipp, AD Leal, JS Voss, JM Hubbard, RR McWilliams, ... Journal of Clinical Oncology 34 (15_suppl), 3529-3529, 2016 | 9 | 2016 |
Christopher LieuUNIVERSITY OF COLORADOVerified email at cuanschutz.edu
